T he 1994 American-European Consensus Conference (AECC) (1) and 2012 Berlin (2) definitions of acute respiratory distress syndrome (ARDS) were developed without pediatric considerations. In 2015, the Pediatric Acute Lung Injury Consensus Conference (PALICC) proposed a definition for pediatric ARDS (PARDS) (3) . PALICC uses oxygenation index (OI) instead of Pao 2 /Fio 2 (mild OI 4 to < 8; moderate 8 to < 16; severe ≥ 16), has alternative stratification Spo 2 -based when Pao 2 is unavailable (oxygen saturation index [OSI] ; mild OSI 5 to < 7.5; moderate 7.5 to < 12.3; severe ≥ 12.3) (4, 5) and has less restrictive radiographic criteria (unilateral vs. bilateral). Undefined in all definitions, however, is specifically when clinicians should measure hypoxemia. Pao 2 / Fio 2 and Spo 2 /Fio 2 are susceptible to ventilator settings (6, 7) , venous admixture (8) , and Fio 2 (9, 10) . OI and OSI adjust for airway pressure, but are affected by treatment response (11) . Berlin does not specify when the Pao 2 /Fio 2 should be measured; PALICC suggests measuring oxygenation at PARDS onset and at 24, 48 , and 72 hours after, without comment regarding superiority.
We (12, 13) and others have demonstrated in pediatric (14) and adult (6, 7) ARDS that oxygenation 24 hours after ARDS onset more accurately discriminates mortality, relative to oxygenation at onset. Thus, 24-hour oxygenation is a better metric for trial enrollment and risk stratification. However, waiting 24 hours is problematic from both a clinical and research perspective, particularly for interventions with greater impact early in ARDS. Therefore, we performed a secondary analysis of an ongoing prospective cohort examining Pao 2 /Fio 2 and OI during the first 24 hours of ARDS to delineate which timepoint before 24 hours would retain utility. Results were validated in an independent PARDS cohort screened using OI or OSI.
METHODS

Derivation Cohort
This was secondary retrospective analysis of an ongoing prospective cohort, approved by the Children's Hospital of Philadelphia's (CHOP) Institutional Review Board (IRB), with requirement for informed consent waived. The cohort has previously been described in detail (12) . Briefly, intubated children meeting AECC criteria for acute lung injury (two consecutive Pao 2 /Fio 2 ≤ 300 separated by ≥ 1 hr with bilateral infiltrates) admitted to the CHOP PICU between July 1, 2011, and June 30, 2016 were enrolled. The CHOP PICU is a 55-bed unit that admits more than 3,500 patients annually, with a 2.7% prevalence of ARDS (12) . As the study was initiated prior to the Berlin definition (2), minimum positive end-expiratory pressure (PEEP) was not specified; however, CHOP PICU does not use PEEP less than 5 cm H 2 O. Thus, all patients met Berlin criteria. Similarly, as the study was initiated prior to the PALICC definition of PARDS (3), we did not screen using OI; however, all but one patient met PARDS criteria by OI. Ventilation and use of ancillary therapies were not protocolized.
Demographics, ventilator settings, Pao 2 /Fio 2 and OI at ARDS onset and at 24 hours, and treatments for the first 3 days were recorded prospectively. ARDS onset was defined by time of initial Pao 2 /Fio 2 . We retrospectively abstracted Pao 2 /Fio 2 and OI at 6, 12, and 18 hours after ARDS onset. All subjects had arterial catheters to be eligible (12) , and blood gases were available at least every 6 hours.
Validation Cohort
A separate cohort of children meeting PALICC PARDS criteria by either OI or OSI from the Children's Hospital of Los Angeles (CHLA) between March 1, 2009, and April 30, 2013, were used for validation (13) . This was approved by the CHLA IRB, and requirement for informed consent waived. PARDS onset was defined by time of initial OI or OSI. Oxygenation was abstracted at PARDS onset, and at 6, 12, 18, and 24 hours after. Because of extensive (> 25%) missing data, we restricted analyses to patients with available oxygenation data at PARDS onset, and at 12 and 24 hours after. ensuring Spo 2 less than or equal to 97%, as previously described (5, 13) . Vasopressor score (15) was dopamine (µg/kg/min) × 1 + dobutamine (µg/kg/min) × 1 + epinephrine (µg/kg/min) × 100 + norepinephrine (µg/kg/min) × 100 + phenylephrine (µg/kg/min) × 100 + vasopressin (U/kg/min) × 10,000 + milrinone (µg/kg/min) × 10. Nonpulmonary organ failures were identified using accepted definitions in children (16) . The designation "immunocompromised" required presence of an immunocompromising diagnosis (oncologic, immunologic, rheumatologic, or transplant) and active immunosuppressive chemotherapy, or a congenital immunodeficiency (12, 17) . Severity of illness score used was the Pediatric Risk of Mortality (PRISM) III at 12 hours.
Equations and Definitions
Outcomes
Primary outcome was PICU mortality. Duration of ventilation and ventilator-free days (VFD) at 28 days were also reported. All mention of "ventilation" implies invasive ventilation; noninvasive support was not counted. "Day 1" was initiation of invasive ventilation. Liberation from invasive ventilation 24 hours or more defined duration of ventilation. Patients requiring reinitiation of invasive ventilation had the extra days counted toward total ventilator days. VFD was determined by subtracting total ventilator days from 28 in survivors. Patients with 28 ventilator days or more and PICU nonsurvivors were assigned VFD equal to 0.
Statistical Analysis
Data are expressed as percentages, means (± sd), or medians (interquartile range). A generalized estimating equation using auto-regressive correlation tested change in oxygenation over time between survivors and nonsurvivors. In some analyses, VFD was dichotomized to less than or equal to 14 or greater than 14 to compute areas under the receiver operating characteristic (AUROC) curve. AUROC tested discriminative ability of Berlin and PALICC definitions using dummy variables for oxygenation categories. A nonparametric test of trend tested if mortality, VFD, or ventilator days in survivors increased across worsening oxygenation categories at different timepoints. Calibration of Berlin and PALICC categories for mortality was assessed by three metrics (18) . First, we performed regression testing association of Berlin or PALICC categories at different timepoints with outcomes. Mortality calibration was assessed with Hosmer-Lemeshow (p < 0.05 implies deviation from prediction, and poor calibration). Next, we plotted predicted (x-axis) versus observed (y-axis) mortality, VFD, or ventilator days in survivors, and reported the slope (perfect calibration = 1, assuming linear relationship between categories and outcomes) and variance explained (r 2 ; perfect calibration = 1). Because VFD incorporates both mortality and length of ventilation, it is a problematic endpoint from which to identify variables associated predominantly with ventilator duration. Therefore, in addition to analyzing VFD and ventilator days in survivors, competing risk regression was used to test the association of Berlin or PALICC severity categories with duration of ventilation at different timepoints after ARDS onset, using extubation as primary outcome, and death as a competing risk. Observations were censored at 28 days. Fine and Gray (19) 
RESULTS
CHOP Cohort
Four hundred fifty-nine children had Berlin-defined ARDS (Supplementary Table 1 
Discriminative Ability of Oxygenation Metrics
Berlin and PALICC categories at ARDS onset did not discriminate mortality, whereas categories at 6, 12, 18, and 24 hours did ( Table 1 ; and Supplementary Fig. 3 , Supplemental Digital Content 5, http://links.lww.com/CCM/D189; legend, Supplemental Digital Content 11, http://links.lww.com/CCM/D195). Berlin and PALICC categories at all timepoints discriminated VFD less than or equal to 14. AUROC improved from 6 to 24 hours for both mortality and VFD less than or equal to 14 for both Pao 2 /Fio 2 and OI, but comparisons between AUROC between 6 and 24 hours were not significant for mortality (p between 0.256 and 0.974). AUROC for VFD less than or equal to 14 were better for Berlin categories at 18 (p = 0.041) and 24 hours (p < 0.001), relative to 6 hours; AUROC for PALICC categories at 24 hours was significantly better than at 6 hours (p < 0.001). Comparisons between Berlin and PALICC categories at the same timepoints were not different for either mortality or VFD less than or equal to 14 (p between 0.114 and 0.899).
Calibration of Oxygenation Metrics for Outcomes
Mortality (Fig. 1) , VFD, ventilator days in survivors, and probability of extubation were plotted against oxygenation categories ( Supplementary Fig. 4 
CHLA Cohort
Two hundred fifty-four children met PALICC criteria for PARDS, of whom 182 had oxygenation recorded at onset, and at 12 and 24 hours (Supplementary Table 3 , Supplemental Digital Content 8, http://links.lww.com/CCM/D192). Eighty-nine subjects (49%) met PALICC criteria using OSI, and 93 (51%) using OI. PRISM III (10 [5, 17] ) was similar to CHOP (11 [5, 17] ; p = 0.882). PALICC categories at onset did not discriminate mortality ( Fig. 6 , Supplemental Digital Content 9, http://links.lww.com/CCM/D193; legend, Supplemental Digital Content 11, http://links.lww.com/CCM/ D195) were plotted against PALICC categories at onset, 12, and 24 hours. At onset, PALICC categories were poorly calibrated. At 12 and 24 hours, calibration for mortality was poor in the CHLA cohort, with r 2 less than or equal to 0.70 at all timepoints. However, VFD, ventilator days in survivors, and probability of extubation all demonstrated improved association with oxygenation severity at 12 and 24 hours, with improved calibration.
Combined Analysis
We analyzed 635 subjects from both cohorts meeting PALICC criteria for PARDS at onset (Supplementary Table 4 six subjects not meeting PALICC criteria at CHOP (only met Berlin initially) were excluded. In this cohort (107 nonsurvivors, 16.9%), PALICC categories discriminated mortality and VFD less than or equal to 14 at all timepoints (Table 1; and Supplementary Fig. 3 , Supplemental Digital Content 5, http:// links.lww.com/CCM/D189--legend, Supplemental Digital Content 11, http://links.lww.com/CCM/D195). As in prior analyses, calibration was poor for all outcomes at PARDS onset, with improved calibration at 12 and 24 hours.
DISCUSSION
Oxygenation at ARDS onset did not discriminate outcomes. By 6 hours, both Berlin and PALICC categories discriminated mortality and demonstrated improved calibration across all outcomes tested. Given the greater consistency of OI (relative to Pao 2 /Fio 2 ), we suggest that OI 6-12 hours after ARDS onset is an appropriate metric for enrollment criteria in clinical trials and is a reliable biomarker for risk stratification. This reduces by more than half the previous timepoint of 24 hours after ARDS for prognostication. Our data have implications for the design of future trials in PARDS.
Multiple studies have demonstrated inadequacy of initial oxygenation in ARDS, relative to oxygenation at 24 hours (6, 7, (12) (13) (14) . Our novel contribution is shortening the timeframe for screening and trial recruitment. This is significant for interventions with greater impact early in ARDS, such as PEEP, recruitment maneuvers, and prone positioning. Oxygenation at PARDS onset did discriminate mortality in the combined cohort, suggesting that lack of discrimination at onset in the CHOP and CHLA cohorts individually was potentially due to infrequent deaths and low power. However, calibration for mortality and ventilator duration was poor at PARDS onset even in the combined cohort, and improved by 12 hours, consistent with our primary analysis. Although the CHOP cohort was screened using Pao 2 /Fio 2 , OI-based categories demonstrated more consistent calibration. This is potentially due to OI accounting for mPaw, making it more independent of ventilator management, whereas Pao 2 / Fio 2 is highly dependent on ventilator strategy. Our study validates the decision by PALICC to use OI, rather than Pao 2 /Fio 2 , as a metric of oxygenation in PARDS (3) . As the CHLA cohort was categorized using either OI or OSI, noninvasive measurements would potentially stratify as well as OI in future studies. This is critical for comparisons between units with differing practices regarding frequency of blood gas measurements, or in placement of arterial catheters.
The CHLA cohort was poorly calibrated for mortality at 12 and 24 hours, although discrimination improved. As this cohort was restricted to the 182 subjects with available oxygenation at onset, 12, and 24 hours, there is possible selection bias toward sicker subjects (more oxygenation measurements). This is suggested by the higher mortality at CHLA (23.1%), relative to CHOP (14.6%; p = 0.014), which potentially affects the reliability of conclusions regarding mortality in the CHLA cohort. Additionally, etiology of death may also contribute to the poor calibration for mortality. The epidemiology of death in PARDS is undescribed, but the frequency of withdrawal for neurologic reasons was comparable with adult data (20) , where 29% of adult ARDS patients had neurologic dysfunction as the primary organ failure precipitating death. Despite heterogeneous causes of death, there was improved calibration for both Berlin and PALICC categories from 6 to 24 hours after ARDS for outcomes based primarily on duration of ventilation in both cohorts.
The lack of a reproducible phenotype, with reliance on measurements prone to variability, such as Pao 2 /Fio 2 and radiographs, has hampered ARDS research (21) . Interventions like higher PEEP (22) and prone positioning (23, 24) may only be efficacious in severe ARDS, and inclusion of less severe phenotypes rendered initial trials negative (25) (26) (27) (28) . Our study suggests that OI measured 6-12 hours after PARDS onset improves reliability of the phenotype, as this metric appropriately discriminates multiple outcomes and is well calibrated across increasing severity classes. Improved classification based on timing has already proven advantageous in adult trials. PROne Positioning in SEVere ARDS (PROSEVA) limited enrollment to patients with Pao 2 /Fio 2 less than 150 and required an additional 12-24 hours of stabilization, after which Pao 2 /Fio 2 less than 150 was confirmed (29) . PROSEVA demonstrated an unprecedented 42% relative reduction in mortality with proning.
Our study has limitations. The two-center nature may limit generalizability, although ARDS etiologies and severity were comparable with others (11, 14, (30) (31) (32) . Ventilator management, sedation, and fluid management was not protocolized, and it is uncertain whether oxygenation measured on standardized settings would improve risk stratification. Our study did not identify an "optimum" timepoint for risk stratification, as we did not measure oxygenation hourly and assess test characteristics. Oxygenation only modestly discriminated mortality and was outperformed by PRISM III (AUROC, 0.74; 95% CI, 0.68-0.79; p = 0.004 relative to OI at 12 hr). However, PRISM III is not designed for risk stratification in ARDS and is generally unavailable at bedside. Additionally, PRISM III was only calibrated for mortality and had no utility for duration of ventilation (median ventilator days of survivors: 10, 9, 11, 10 across increasing quartiles of PRISM score; p for trend = 0.323). Finally, eligibility at CHOP was based on Pao 2 /Fio 2 , not OI, as the study was initiated prior to publication of PALICC, precluding us from making firm statements regarding utility of PALICC categories based on timing. However, 453 of 459 children (99%) met PALICC criteria by OI simultaneous with meeting Berlin criteria, and five of the six not initially meeting PALICC criteria met OI criteria within 6 hours, making this unlikely to invalidate our findings.
Our study has several strengths. The derivation cohort was a large, prospective ARDS cohort from a large PICU, with detailed data collection. Results were validated in a separate large quaternary PICU. We tested association of Berlin and PALICC categories with a range of outcomes. The association with multiple outcomes is necessary in PARDS, where mortality is low, and often unrelated to lung injury. The utility of OI as early as 6 hours after ARDS onset significantly improves upon the previously reported 24 hours. These results have critical implications for the design of trials in PARDS.
